(Q35043124)

6 August 2017

1 reference

title

Renal and cardiovascular considerations for the nonpharmacological and pharmacological therapies of obesity-hypertension (English)

1 reference

6 August 2017

0 references

Zhang R

1

1 reference

6 August 2017

Thakur V

series ordinal

2

1 reference

6 August 2017

Morse S

series ordinal

3

1 reference

6 August 2017

Reisin E

series ordinal

4

1 reference

6 August 2017

publication date

1 December 2002

1 reference

Journal of Human Hypertension

6 August 2017

published in

1 reference

6 August 2017

volume

16

1 reference

6 August 2017

issue

12

1 reference

6 August 2017

page(s)

819-827

1 reference

The effect of age on the association between body-mass index and mortality.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Influence of race, sex and weight on blood pressure behavior in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Obesity-hypertension: the effects on cardiovascular and renal systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

21 January 2018

Obesity and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Effect of Weight Loss without Salt Restriction on the Reduction of Blood Pressure in Overweight Hypertensive Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Insulin Secretion in Obesity and Diabetes: An Illustrative Case

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Effect of Diet Composition on the Hyperinsulinemia of Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Cardiovascular effects of weight reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Cardiovascular Changes After Weight Reduction in Obesity Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Serum immunoreactive-leptin concentrations in normal-weight and obese humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Weight reduction and pharmacologic treatment in obese hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [seecomments]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Expression of natriuretic peptide receptors in human adipose and other tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Practical aspects of dietary management of hypertension: compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Comparison of nifedipine alone and with diltiazem or verapamil in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Obesity as a determinant for response to antihypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

beta Blockade after myocardial infarction: systematic review and meta regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

21 January 2018

Drug therapy. Prazosin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Comparative Effects of Antihypertensives on Proteinuria: Angiotensin-Converting Enzyme Inhibitor Versus α1-Antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

The relation of adiposity to blood pressure and development of hypertension. The Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Obesity-induced hypertension. Renal function and systemic hemodynamics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

1 reference

7 January 2021

Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Differential effects of calorie restriction on glomeruli and tubules of the remnant kidney

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

A low-calorie unrestricted protein diet attenuates kidney damage in uninephrectomized spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Comparison between moexipril and atenolol in obese postmenopausal women with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

The treatment of obese hypertensive black women: a comparative study of chlorthalidone versus clonidine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Insulin sensitivity, glucose effectiveness, and beta-cell function in obese males with essential hypertension: investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinap

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Class differences in the effects of calcium channel blockers in the rat remnant kidney model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Role of sympathetic nerve inhibition and body sodium-volume state in the antihypertensive action of clonidine in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001496

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1001496

1 reference

6 August 2017

1 reference